Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics

BACKGROUND: Extending endocrine therapy from 5 to 10 years is recommended for women with invasive estrogen receptor (ER)‐positive breast cancers. We evaluated the benefits and harms of the five additional years of therapy. METHODS: An established Cancer Intervention and Surveillance Network (CISNET)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandler, Young, Schechter, Clyde, Jayasekera, Jinani, Isaacs, Claudine, Kurian, Allison W., Cadham, Christopher, Mandelblatt, Jeanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729060/
https://www.ncbi.nlm.nih.gov/pubmed/34918484
http://dx.doi.org/10.1002/cam4.4084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729060/
https://www.ncbi.nlm.nih.gov/pubmed/34918484
http://dx.doi.org/10.1002/cam4.4084

Ejemplares similares